Zacks Investment Management Intra Cellular Therapies, Inc. Transaction History

Zacks Investment Management

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $10,896 - $17,307	235 Added 1.53%	15,569 $1.12 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $272,795 - $335,691	5,237 Added 51.87%	15,334 $798,000
Q2 2023 Aug 15, 2023	BUY	$54.67 - $66.44 $66,424 - $80,724	1,215 Added 13.68%	10,097 $639,000
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $60,629 - $73,681	-1,109 Reduced 11.1%	8,882 $562,000
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $49,406 - $64,284	1,128 Added 12.73%	9,991 $541,000
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $16,614 - $20,527	377 Added 4.44%	8,863 $469,000
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $55,595 - $78,106	1,302 Added 18.12%	8,486 $395,000
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $308,912 - $471,557	7,184 New	7,184 $410,000

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

Stay updated on Zacks Investment Management with notifications on news.